By Dan Primack
May 20, 2013

Karyopharm Therapeutics Inc., a Natick, Mass.-based developer of nuclear transport modulators, has raised $48.2 million in Series B funding. Delphi Ventures was joined by an undisclosed “private investor.” www.Karyopharm.com

Effector Therapeutics, a San Diego-based developer of small molecule selective translation regulators for cancer, has raised $45 million in Series A funding. Backers include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital. www.effector.com

Alteryx Inc., an Irvine, Calif.-based provider of strategic analytics, has raised $12 million in new VC funding from Toba Capital and return backer SAP Ventures. www.alteryx.com

Zyme Solutions, a Redwood Shores, Calif.-based provider of channel data management solutions, has raised $5 million in new VC funding from Susquehanna Growth Equitywww.zymesolutions.com

Sign up for Dan’s daily email newsletter on deals and deal-makers: GetTermSheet.com

You May Like

EDIT POST